Aortic in Biological Technology

ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons

... ATS's broad product offering is the ATS 3f(R) aortic Bioprosthesis designed to replace the patient's diseased valve. The ATS 3f aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve with ...

ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis

... FDA clearance for the marketing of the ATS 3f(R) aortic Bioprosthesis that includes a new sewing ... ) While the ATS 3f aortic Bioprosthesis PMA was approved on October ... on track with the previous guidance. The ATS 3f aortic Bioprosthesis is the Company's first entry into ...

Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval

... Less Invasive Surgical Options for Patients with aortic Aneurysms ... invasive device for the treatment of abdominal aortic aneurysms (AAA). The procedure was performed at ... repaired a 6 cm aneurysm in a patient having an aortic neck diameter of 30 mm. AAA is a weakening in ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... their test results for heart disease, abdominal aortic aneurysm, stroke, peripheral artery disease, ... of stroke and heart disease. -- Abdominal aortic Aneurysm (AAA) Screening -- Multiple ... the body, indicate any abnormal enlargement. An aortic aneurysm can occur anywhere along the aorta, but ...

CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure

... The Ross Procedure is a type of specialized aortic valve surgery in which the patient's diseased aortic valve is replaced with his or her own pulmonary ... offers several advantages over other traditional aortic valve replacement options. The most important ...

CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries

... added Dr. Ormiston. "Currently, percutaneous aortic valve replacement (PAVR) is used for carefully ... sustained, PAVR may substitute for traditional aortic valve replacement surgery in more patients." ... ReValving System allows both percutaneous aortic valve replacement (PAVR) and ...

Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets

... Japanese and Canadian aortic stent graft market to grow at CAGRs of nearly ... Peripheral Vascular (PV) Devices 2008 report, the aortic stent graft market will increase at a compound ... technologies will allow more patients with aortic disease to be treated using endovascular ...

Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008

... implantation of the Edwards SAPIEN transcatheter aortic heart valve in more than 1,000 patients ... The start of patient enrollment for transcatheter aortic valve replacement procedures with the ... PERIMOUNT Magna pericardial aortic heart valve. As the first and only device of its ...

ATS Medical Announces Record Quarterly Revenue and Gross Profit

... mid 2008. Tissue Heart Valves -- ATS 3f(R) aortic Bioprosthesis: The Company's first generation ... in support of its PMA for the ATS 3f aortic Bioprosthesis. The Company submitted answers ... continues to expect that the ATS 3f aortic Bioprosthesis will be approved in the second ...

CryoLife Conducts Surgeons Cardiac Allograft Symposium

... outcomes, indications and surgical techniques of aortic valve replacement utilizing aortic allografts and the CryoValve(R) SG pulmonary ... the newest surgical techniques utilizing human aortic valves and our recently FDA-cleared CryoValve ...

ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease

... it has received a CE Mark approval for its Open aortic Stapler (OAS) system for mechanical suturing technology of aortic synthetic grafts during open repair of AAA and other aortic reconstructions, enabling commercialization of ...

ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis

... American commercial implant of the ATS 3f(R) aortic Bioprosthesis. Canadian regulatory approval was ... Canada. The patient was a 76-year-old man with aortic valve stenosis. The valve replacement was ... ) The ATS 3f aortic Bioprosthesis incorporates revolutionary ...

Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve

... of the next-generation Edwards transcatheter aortic heart valve, performed by John Webb, ... broader group of patients suffering from severe aortic stenosis," said Webb, who along with his ... team has performed more than 150 transcatheter aortic valve replacement procedures. "Providing patients ...

Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve

... trial of the Edwards SAPIEN transcatheter aortic heart valve technology. The FDA approved the ... to 1,040 patients. The PARTNER (Placement of aortic traNscathetER valves) trial, initiated in the ... calcific aortic stenosis -- a narrowing of the aortic valve that reduces the outward flow of oxygenated ...

Children's Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey

... artery bypass graft, percutaneous coronary intervention, abdominal aortic aneurysm repair, aortic valve replacement, pancreatic resection, esophagectomy and bariatic ...

Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program

... and intellectual property related to the TriVascular endovascular aortic repair (EVAR) program. Terms of the sale include $30 million in cash paid ... was founded to develop EVAR devices and procedures for treating abdominal aortic aneurysms, in April 2005. Boston Scientific discontinued its EVAR program ...

Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic

... us to expand clinical trials of our core technologies, the Trilogy(TM) aortic Valve System and the sutureless TRE(TM) implantation tool. These devices ... significant clinical benefits to patients worldwide. The Trilogy(TM) aortic Valve System and TRE(TM) attachment technologies are designed to expand ...

LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer

... replacement and repair surgeries, predominantly open abdominal aortic aneurysm ("AAA") repair. Biomateriali has been manufacturing these ... "LeMaitre Vascular can now offer implants for both endovascular and open aortic repair." "Biomateriali's high quality vascular grafts fit well in our ...

Edwards Lifesciences Forecasts Strong Growth in 2008

... designed to expand the treatment options for patients with severe aortic stenosis through minimally-invasive therapies. In Europe, the company ... Hospital, who will detail their clinical experience with transcatheter aortic valve therapies. Webcast Information The Edwards Lifesciences 2007 ...

CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium

... will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provide a practical laboratory in which to ...

Signostics Receives FDA Clearance for World's Smallest Ultrasound Product

... delivers high-resolution images anywhere, at any time for general medical applications, including: abdominal assessments such as bladder, abdominal aortic aneurysm screening, and trauma assessment; musculoskeletal; and basic obstetrics, such as pregnancy viability and fetal positioning. According ...

CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. For additional information about the company, visit CryoLife's ...

CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. For additional information about the Company, visit ...

Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)

... on our blog, at www.deCODEyou.com . deCODEme Cardio(TM) measures 8 SNPs associated with the risk of heart attack, intracranical and abdominal aortic aneurysm, stroke and atrial fibrillation, peripheral arterial disease (PAD) and venous thromboempolism. deCODEme Cancer(TM) measures 29 SNPs ...

CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. Statements made in this press release that look forward in time ...

CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. For additional information about the company, visit CryoLife's ...

CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. Statements made in this press release that look forward in time ...

CryoLife to Present at UBS Global Life Sciences Conference

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. For additional information about the Company, visit CryoLife's ...

Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device

... diagnostic and therapeutic procedures. Since its founding in 1963, Cook has created innovative technologies for drug-eluting and bare metal stents, aortic and vascular endografts, catheters, wire guides, introducer needles and sheaths, embolization coils, medical biomaterials and contract manufacturing ...

CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida

... for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine aortic Bioprosthesis, which is CE marked for distribution within the European Community. Statements made in this press release that look forward in time ...

Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today

... Ph.D., Chief, Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, and the primary investigator of Simvastatin plus Ezetimibe in aortic Stenosis study (SEAS), has announced that he will present an update on the study at 1 p.m. (U.S. EDT) today. To listen live to the Schering-Plough ...

Peripheral Vascular Device Market Insights Webinar

... and launches by existing and new competitors -- Results of supportive clinical data on device usage patterns Thoracic Endovascular aortic Repair (TEVAR) Market -- Market impact of emerging competitors A question and answer session will follow the presentation. To enroll for this ...

deCODE genetics Announces First Quarter 2008 Financial Results

... genetic factors involved in prostate cancer, breast cancer, nicotine addiction and lung cancer, osteoporosis, intracranial and abdominal aortic aneurysm, and human fertility and evolution. -- Heart attack - DG051. In January, the company announced positive results from its Phase IIa ...

Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations

... pulmonary artery catheter, which established the foundation for hemodynamic monitoring; and more recently, the first "beating heart" transcatheter aortic valve replacement. "We take great pride in our 50-year heritage of working as trusted partners with clinicians to develop innovative technologies ...

CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve

... defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG is then surgically implanted in place of the removed native pulmonary ...

deCODE Genetics Announces Full-year 2007 Financial Results

... a common precursor of stroke; deCODE MI(TM), a test for a major genetic risk factor for early-onset heart attack as well as abdominal aortic and intracranial aneurysms; deCODE ProCa(TM), which detects several significant genetic risk variants for prostate cancer; and we have ...

CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves

... defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG is then surgically implanted in place of the removed native pulmonary ...

Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination

... for the 24-week study period. The effect of the combination treatment of APA-01 combined with atorvastatin appeared to cause a trend toward decreased aortic lesions, but these were not statistically significant. Commenting on the study results, Dr. Esra Ogru, Executive Vice President of Research and ...

Edwards Lifesciences Completes Acquisition of CardioVations Product Line

... on earnings in 2008 and will be accretive thereafter. "We are pleased to add CardioVations' unique products to Edwards' portfolio of innovative aortic and mitral valve replacement technologies," said Anita B. Bessler, Edwards' corporate vice president, heart valve and cardiac surgery systems. "This ...

Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors

... to introducing nine new patient monitoring products in 2007, our new Sensation(TM) 7 Fr. fiber-optic balloon catheter and the CS300 intra aortic balloon pump (IABP) underscore Datascope's leadership position in the Cardiac Assist market. -- Continued investment in Research & Development. ...